CD34 and myelodysplastic syndrome: To explore the molecular mechanisms and biological implications that drive the clonal advantage of SF mutant cells over their wild-type counterparts, we conducted single-cell RNA sequencing on CD34+ cells from MDS patients, either without SF mutations (n = 5) or with the U2AF1 S34F mutation (n = 3).